These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 8558431)
21. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Aktaş Y; Yemisci M; Andrieux K; Gürsoy RN; Alonso MJ; Fernandez-Megia E; Novoa-Carballal R; Quiñoá E; Riguera R; Sargon MF; Celik HH; Demir AS; Hincal AA; Dalkara T; Capan Y; Couvreur P Bioconjug Chem; 2005; 16(6):1503-11. PubMed ID: 16287248 [TBL] [Abstract][Full Text] [Related]
22. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. Cerletti A; Drewe J; Fricker G; Eberle AN; Huwyler J J Drug Target; 2000; 8(6):435-46. PubMed ID: 11328669 [TBL] [Abstract][Full Text] [Related]
23. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pardridge WM; Kang YS; Buciak JL Pharm Res; 1994 May; 11(5):738-46. PubMed ID: 8058646 [TBL] [Abstract][Full Text] [Related]
24. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. Song BW; Vinters HV; Wu D; Pardridge WM J Pharmacol Exp Ther; 2002 May; 301(2):605-10. PubMed ID: 11961063 [TBL] [Abstract][Full Text] [Related]
25. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Muzykantov VR; Murciano JC; Taylor RP; Atochina EN; Herraez A Anal Biochem; 1996 Oct; 241(1):109-19. PubMed ID: 8921172 [TBL] [Abstract][Full Text] [Related]
26. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier. Poduslo JF; Curran GL; Haggard JJ; Biere AL; Selkoe DJ Neurobiol Dis; 1997; 4(1):27-34. PubMed ID: 9258909 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of [3H]biotin bound to different avidin analogues. Kang YS; Saito Y; Pardridge WM J Drug Target; 1995; 3(2):159-65. PubMed ID: 7496729 [TBL] [Abstract][Full Text] [Related]
28. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. Liu X; Smith BJ; Chen C; Callegari E; Becker SL; Chen X; Cianfrogna J; Doran AC; Doran SD; Gibbs JP; Hosea N; Liu J; Nelson FR; Szewc MA; Van Deusen J J Pharmacol Exp Ther; 2005 Jun; 313(3):1254-62. PubMed ID: 15743928 [TBL] [Abstract][Full Text] [Related]
29. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187 [TBL] [Abstract][Full Text] [Related]
30. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021 [TBL] [Abstract][Full Text] [Related]
31. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. Pardridge WM; Yoshikawa T; Kang YS; Miller LP J Pharmacol Exp Ther; 1994 Jan; 268(1):14-8. PubMed ID: 8301550 [TBL] [Abstract][Full Text] [Related]
32. Transport of recombinant CD4 through the rat blood-brain barrier in vivo. Pardridge WM; Buciak JL; Yoshikawa T J Pharmacol Exp Ther; 1992 Jun; 261(3):1175-80. PubMed ID: 1602382 [TBL] [Abstract][Full Text] [Related]
33. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. Bickel U; Schumacher OP; Kang YS; Voigt K J Pharmacol Exp Ther; 1996 Jul; 278(1):107-13. PubMed ID: 8764341 [TBL] [Abstract][Full Text] [Related]
34. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Schnyder A; Krähenbühl S; Török M; Drewe J; Huwyler J Biochem J; 2004 Jan; 377(Pt 1):61-7. PubMed ID: 14516278 [TBL] [Abstract][Full Text] [Related]
35. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. Pardridge WM; Triguero D; Yang J; Cancilla PA J Pharmacol Exp Ther; 1990 May; 253(2):884-91. PubMed ID: 2338660 [TBL] [Abstract][Full Text] [Related]
36. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Poduslo JF; Curran GL; Sanyal B; Selkoe DJ Neurobiol Dis; 1999 Jun; 6(3):190-9. PubMed ID: 10408808 [TBL] [Abstract][Full Text] [Related]
37. Brain iron homeostasis. Moos T Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165 [TBL] [Abstract][Full Text] [Related]
38. Transport of histone through the blood-brain barrier. Pardridge WM; Triguero D; Buciak J J Pharmacol Exp Ther; 1989 Dec; 251(3):821-6. PubMed ID: 2600816 [TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Kurihara A; Deguchi Y; Pardridge WM Bioconjug Chem; 1999; 10(3):502-11. PubMed ID: 10346884 [TBL] [Abstract][Full Text] [Related]
40. In vivo and in vitro evidence for nonrestricted transport of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein tetraacetoxymethyl ester at the blood-brain barrier. Hirohashi T; Terasaki T; Shigetoshi M; Sugiyama Y J Pharmacol Exp Ther; 1997 Feb; 280(2):813-9. PubMed ID: 9023295 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]